Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Prilosec OTC, Nexium Launches Fed “Shark Fin” Monopoly Plan, Suit Claims

This article was originally published in The Tan Sheet

Executive Summary

Elements of the Prilosec OTC launch, ranging from the drug's 14-day term of use to supply shortages during its time on the market, were part of a plan by AstraZeneca to interfere with generic competition for its prescription proton pump inhibitors, retailers allege in a lawsuit against the U.K. drug maker

You may also be interested in...

Follow-On Brand Drugs Could Draw FTC Anticompetitive Scrutiny

The introduction of certain follow-on brand drugs as the original product nears patent expiration could raise anticompetitive concerns at the Federal Trade Commission, according to FTC Commissioner Pamela Harbour

Prilosec OTC Shortages Due To Inaccurate Projections, Global Supply Chain

Procter & Gamble is building up enough Prilosec OTC inventory to allow retailers to re-launch the product

Esperion Aiming For 50% Commercial Coverage For Nexletol

The company hopes to sidestep payer restrictions and patient abandonment by launching the cholesterol-lowering medicine at a palatable price point in line with where branded statins were before patent expiry.





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts